A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis

Overview of attention for article published in American Journal of Obstetrics & Gynecology, September 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 16 news outlets
policy: 1 policy source
twitter: 15 X users

facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 32 news stories from 16 outlets.

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC (secnidazole)

FirstWord Pharma, 01 Feb 2021

MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ -- Lupin Pharmaceuticals Inc.

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole)

Finanzen, 01 Feb 2021

A A Teilen Drucken MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ -- Lupin Pharmaceuticals Inc.

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole)

Finanzen.ch, 01 Feb 2021

MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ -- Lupin Pharmaceuticals Inc.

Lupin Announces Partnership with Phil, Inc. in Support of SOLOSEC® (secnidazole)

Ticker Tech, 01 Feb 2021

MUMBAI, India and BALTIMORE, Feb. 1, 2021 /PRNewswire/ -- Lupin Pharmaceuticals Inc.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 28 additional news stories.